PhaseRx, Inc. announced the appointment of Gordon Brandt, M.D., as chief medical officer. The addition of Dr. Brandt, a recognized industry leader in clinical development, bolsters PhaseRx's strategy of assembling a world-class executive team. Dr. Brandt previously served as PhaseRx's chief clinical advisor, and has been working with the company for five years. Prior to this, he served as president and executive vice president of clinical research and medical affairs for Nastech Pharmaceutical Company Inc. (which became MDRNA Inc.), where he worked to develop nucleic acid therapeutics.